DANVERS, Mass., May 10 /PRNewswire-FirstCall/ -- Medwave Inc. announced today that it is launching a new product addition to its revolutionary family of non-invasive, sensor-based blood pressure solutions. The new product, PRIMO(TM), which combines Medwave's clinically proven blood pressure sensor and software technology with a new user interface and package, will be demonstrated and exhibited from May 10th-12th at the NTI/AACN held in New Orleans, LA at the Ernest N. Morial Convention Center.
Rich Niemczyk, Product Marketing Manager for Medwave, stated, "The PRIMO(TM) is a hand-held blood pressure monitor designed to automatically take individual spot-check blood pressure readings. The new design exemplifies form, fit and function. The term "PRIMO," which in music means first or leading, is an apt name for our automatic hand-held blood pressure monitor, as we view it as the first of what we expect to be many more future developments for Medwave."
Medwave's President and CEO, Tim O'Malley, added, "The spot blood pressure monitoring market is estimated at approximately $500 million annually including all of the various segments of the market. Medwave has developed what may be the most advanced way to read spot blood pressures in a multitude of clinical environments. Over the past several months, numerous clinical research papers have been published in leading medical journals regarding Medwave's sensor technology. All of the studies clearly state that Medwave's sensor technology works as well as a blood pressure cuff in normal situations, and in challenging situations, compares favorably to an invasive catheter. We believe that PRIMO(TM) has the capability of spreading this utility into almost any clinical setting. The PRIMO(TM) product is the culmination of the efforts of a talented team of individuals from our facilities in Arden Hills, MN and Danvers, MA. I could not be more pleased with the result."
Medwave, Inc. develops, manufactures, and distributes sensor-based non-invasive blood pressure solutions. Its Vasotrax(R) Hand Held Monitor, the Vasotrac(R) APM205A NIBP Monitor, the Vasotrac(R) APM205A Model DS, and the MJ23 OEM Module are new approaches to non-invasive blood pressure monitoring. Medwave's latest addition, the Legato(TM) OEM Developers Kit, is designed to introduce the innovated Vasotrac(R) technology to OEM designers. Medwave has received the necessary regulatory clearances to market its technology in Europe, Asia, and the United States. Medwave is ISO13485/ISO9001/MDD93/42/EEC certified, and its products are CE marked. Medwave has received the Seal of Acceptance from the Alliance of Children's Hospitals, as well as the Frost and Sullivan Market Engineering Award for Technology Innovation. Medwave's technology is installed in over 500 hospitals and clinics worldwide. Medwave currently has supply and/or other agreements with Nihon Kohden, Zoll Medical Corporation, Analogic Corporation, and a global electronics company. Medwave trades on the NASDAQ small cap market under the symbol MDWV. For more information, visit http://www.medwave.com/.
Statements made in this release that are stated as expectations, plans, anticipations, prospects or future estimates or which otherwise look forward in time are considered "forward-looking statements" and involve a variety of risks and uncertainties, known and unknown, which are likely to affect the actual results. The following factors, among others, as well as factors discussed in the Medwave's filings with the SEC, have affected and, in the future, could affect Medwave's actual results: resistance to the acceptance of new medical products, the market acceptance of the Vasotrac(R) system and other products of Medwave, hospital budgeting cycles, the possibility of adverse or negative results or commentary from clinical researchers or other users or evaluators of Medwave's products, Medwave's success in creating effective distribution channels for its products, Medwave's ability to scale up its manufacturing process, and delays in product development or enhancement or regulatory approval. Consequently, no forward-looking statement can be guaranteed and actual results may vary materially. Medwave(R), Vasotrac(R), Vasotrax(R), Legato(TM), and Primo(TM) are trademarks of Medwave, Inc. The Primo(TM) does not comply with the United States FDA premarket notification regulations. Medwave, Inc. does not intend to introduce the Primo(TM) into commercial distribution at this time. The Primo(TM) is an investigational device only.
Investors/Media: Contacts: Stephanie Carrington/Greg Tiberend Jodie Chastain The Ruth Group Medwave, Inc. 646-536-7017/7005 800-894-7601 scarrington@theruthgroup.comjchastain@mdwv.comgtiberend@theruthgroup.com
Medwave Inc.CONTACT: investors/press, Stephanie Carrington, +1-646-536-7017, orscarrington@theruthgroup.com, or Greg Tiberend, +1-646-536-7005, orgtiberend@theruthgroup.com, both of The Ruth Group, for Medwave, Inc.; orJodie Chastain of Medwave, Inc., 800-894-7601, or jchastain@mdwv.com
Web site: http://www.medwave.com/